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Background: Parecoxib sodium is the first parenteral COX-2 inhibitor used for pain management licensed for
postoperative pain. However, no study has assessed the usage of parecoxib for acute traumatic pain in the
emergency department (ED). The objective of this study was to investigate a potential alternative analgesic agent
in the ED by determining the mean reduction of pain score between acute traumatic pain patients who were
administered with intravenous (IV) parecoxib sodium versus IV morphine sulfate. The onset of perceptible analgesic
effect and side effects were also evaluated.
Methods: A randomized, double-blinded study comparing IV parecoxib 40 mg versus IV morphine at 0.10 mg/kg
was conducted in adult patients presented with acute traumatic pain with numeric rating scale (NRS) of 6 or
more within 6 hours of injury. Patients were randomized using a computer-generated randomization plan. Drug
preparation and dispensing were performed by a pharmacist. Periodic assessment of blood pressure, pulse rate,
oxygen saturation, and NRS were taken at 0, 5, 15, and 30 minute intervals after the administration of the study
drug. The primary outcome was the reduction of NRS. Side effect and drug evaluation was conducted within
30 minutes of drug administration.
Results: There was no statistically significant difference in the reduction of mean NRS between patients in the IV
parecoxib group or IV morphine group (P = 0.095). The mean NRS for patients treated with IV morphine were
7.1 at 0 minutes, 4.5 at 5 minutes, 3.1 at 15 minutes, and 2.0 at 30 minutes. Whereas mean NRS for patients who
received IV parecoxib were 7.8 at 0 minutes, 5.7 at 5 minutes, 4.7 at 15 minutes, and 3.9 at 30 minutes. The onset
of perceptible analgesic effects could be seen as early as 5 minutes. Dizziness was experienced in 42.9% of patients
who received IV morphine compared to none in the parecoxib group.
Conclusions: There was non-significant trend toward superiority of IV morphine over IV parecoxib. Looking at its
effectiveness and the lack of opioid-related side-effects, the usage of IV parecoxib sodium may be extended further
to a variety of cases in the ED.Background
Parecoxib sodium is the first parenteral COX-2 inhibitor
available for clinical use in pain management [1]. Based
on data of clinical trials, its peak serum concentrations
occur about 30 minutes after intravenous (IV) admi-
nistration and 1 hour after intramuscular (IM) injection.
Its first perceptible analgesic effect occurred within 7 to* Correspondence: amararyff@kb.usm.my
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in any medium, provided the original work is p13 minutes, with clinically meaningful analgesia demon-
strated within 23 to 39 minutes and a peak effect within
2 hours following administration of single doses of
40 mg by IV or IM injection [2].
The efficacy of parecoxib sodium was established in
multiple postoperative pain studies including gynecology
and orthopedic surgery [3-7]. The analgesic efficacy of
parecoxib sodium 20 and 40 mg, IV or IM, has been
found to be similar to that of Ketorolac, 15 to 30 mg IV
and 30 to 60 mg IM, and IV morphine 12 mg [3,4]. The
advantages of this analgesic include its additive effectis is an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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shown in multiple studies [5,6,8].
In the United Kingdom, IV parecoxib sodium is licensed
for short-term treatment for postoperative pain [8]. A
study regarding the use of parecoxib for postoperative
pain showed that a single dose of parecoxib 20 mg or
40 mg provided effective analgesia for 50% to 60% of those
treated compared to about 15% with placebo and was well
tolerated [1]. Another multicenter study in Latin America
looked at the use of parecoxib in acute renal colic and it
showed parecoxib to be as effective as ketoprofen in the
treatment of renal colic [9].
The appropriate usage of IV parecoxib sodium in the
emergency department (ED) is not well established. To
the best of our knowledge, there was no study regarding
parecoxib sodium usage in the ED for acute traumatic
pain. Therefore, the objective of this study was to inves-
tigate a potential alternative analgesic agent in the ED by
determining the mean reduction of pain score between
acute traumatic pain patients who were administered
with IV parecoxib sodium versus IV morphine sulfate.
Since time is essential in the ED, the onset of perceptible
analgesic effect was determined and the side effects were
evaluated.
Methods
A randomized, double-blinded study comparing IV mor-
phine sulfate at 0.10 mg/kg versus IV parecoxib sodium
40 mg was conducted in adult patients in the ED of
Hospital Universiti Sains Malaysia (HUSM) from 1st
August 2010 until 31st March 2011. HUSM is a tertiary
centre located at the northeast of Peninsular Malaysia with
750 beds availabile for adult and pediatric patients. The an-
nual census of the ED in 2009 was 56,662 cases, including
all trauma and non-trauma cases. The annual census for
orthopedic cases was 1,685 cases, which represents 3% of
the total cases per annum [10]. Ethical approval was ob-
tained from the Human Ethics Committee of Universiti
Sains Malaysia and short-term research grant money from
the university was used to buy the study drug (parecoxib
sodium) as it was not a standard item in the ED.
Adult patients (aged 18 years and above) with signifi-
cant acute traumatic pain who presented to the ED of
HUSM within 6 hours of trauma were included. Signifi-
cant acute traumatic pain was defined as pain score
based on numeric rating scale (NRS) of 6 or more
following trauma that involved bony fracture or soft
tissue injury. Head injury cases with Glasgow Coma
Scale ratings less than 15/15, intoxicated patients, preg-
nant patients, hemodynamically unstable patients, patients
with a significant language barrier, or patients allergic to
morphine, parecoxib sodium, or any non-steroidal anti-
inflammatory drug or on any type of analgesia within the
preceding 6 hours, were excluded.All patients in the ED were triaged and the triager
would alert the researchers once traumatic patients with
a NRS of 6 or more had presented. Patients were
brought to the treatment area by researchers and written
informed consents were obtained. Focused history and
physical examination were carried out by emergency
residents on duty. Immobilization and splinting of the
limbs and dressing of wounds were done according to
the injuries. In the meantime, the pharmacist in charge
was alerted regarding the patients’ body weight for drug
randomization and preparation. All patients were ran-
domized using a computer-generated randomization
plan to receive IV parecoxib sodium 40 mg or IV
morphine sulfate 0.1 mg/kg. To ensure researchers,
emergency residents on duty, nurses, and patients were
blinded to the treatment, the randomization was con-
ducted by the pharmacist and he/she was responsible for
preparation and dispensing of the study drug. The study
drugs were administered by emergency residents once it
was ready.
Periodic assessment of blood pressure, pulse rate,
oxygen saturation, and NRS were taken at 0, 5, 15,
and 30 minute intervals after the administration of
the study drug. The assessment was conducted by the
researchers who were kept blinded about the treatment.
After 30 minutes of observation, if the NRS was 6 or
more, a rescue drug (IV morphine sulfate 0.1 mg/kg) was
administered to the patient by the emergency resident on
duty. Side effects of the study drug were evaluated within
30 minutes of drug administration by asking the patients
about any unwanted symptoms. Radiological investigation
of the affected limb was taken, if indicated after 30-minute
period of observation was over. Patients were then
referred to the respective teams at the end of the study
according to their injuries.
The primary outcome in this study was the reduction
of pain score based on the NRS. The satisfaction of the
study drug was assessed by asking patients “In terms of
your satisfaction, how would you rate this pain medica-
tion?” 30 minutes after IV administration, using the scale
“poor”, “fair”, “good”, and “excellent”.
We hypothesized that there would not be a significant
trend towards IV morphine being superior to IV pare-
coxib for pain reduction in acute trauma pain in the ED.
Data entry and analysis were done using the Statistical
Package for Social Science (SPSS) version 12.0 software.
The statistical analysis included descriptive analysis such
as mean, standard deviation, percentage, paired t-test,
and repeated measure ANOVA.
The parecoxib sodium used in this study was manufac-
tured by Pharmacia & Upjohn Kalamazoo, Michigan,
USA; it was produced for Pfizer using the trade name of
Dynastat. Each vial of Dynastat contains 40 mg of pare-
coxib sodium for reconstitution. After reconstitution,
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morphine sulfate was manufactured by Duopharma (M)
Sdn Bhd, Selangor, Malaysia. Each milliliter of injection
contained 10 mg of morphine sulfate. The dosage for IV
morphine was 0.1 mg/kg. Once the dosage was calcu-
lated based on body weight, the pharmacist would
prepare the morphine solution and dilute it to 2 mL of
volume; this made parecoxib and morphine appeared
identical.
Results
A total of 32 patients, including 26 males and 6 females,
were enrolled in the study. The youngest patient was 19
years old whereas the oldest was 65 years old. Eighteen
patients received IV parecoxib sodium as an analgesic
whereas 14 patients received IV morphine. Patients with
a bone fracture were equal in number for both groups.
Soft tissue injuries were administered parecoxib and
morphine in 10 cases and 6 cases, respectively. Mean
NRS were 7.1 ± 1.3 for the morphine group and 7.8 ± 1.3
for the parecoxib group (Table 1).Table 1 Socio-demographic and clinical characteristic





Mean (SD)/n (%) Mean (SD)/n (%)
Age 34.5 (14.7) 36.9 (15.3)
Gender
Male 11 (78.6) 15 (83.3)
Female 3 (21.4) 3 (16.7)
NRS
Mean (SD) 7.1 (1.3) 7.8 (1.3)
Traumatic injury
Soft tissue injury 6 (42.9) 10 (55.6)
Bone fracture 8 (57.1) 8 (44.4)
Side effect
Dizziness 6 (42.9) 0 (0.0)
Stomach upset 0 (0.0) 0 (0.0)
Allergic reaction 0 (0.0) 0 (0.0)
Nausea 0 (0.0) 0 (0.0)
No side effects 8 (57.1) 15 (83.3)
Rescue drugs
Required 1 (7.1) 5 (27.8)
Not required 13 (92.9) 13 (72.2)
Drug evaluation
Excellent 7 (50.0) 4 (22.2)
Good 7 (50.0) 11 (61.1)
Fair 0 (0.0) 2 (11.1)
Poor 0 (0.0) 1 (5.6)There was no statistically significant difference in the
reduction of mean NRS between patients that were
treated with either IV parecoxib or morphine (P = 0.095).
The mean NRS for patients that were treated with IV
morphine were 7.1 at 0 minutes, 4.5 at 5 minutes, 3.1 at
15 minutes, and 2.0 at 30 minutes. Mean NRS for patients
who received IV parecoxib were 7.8 at 0 minutes, 5.7 at 5
minutes, 4.7 at 15 minutes, and 3.9 at 30 minutes (Table 2).
Figure 1 shows the estimated mean of NRS between
patients treated with IV parecoxib or morphine within 0
to 30 minutes. The mean reduction of NRS for patients
treated with IV parecoxib and IV morphine between
0–5 minutes, 0–15 minutes, 0–30 minutes, 5–15 minutes,
5–30 minutes, and 15–30 minutes were significant
(Table 3).
Dizziness was experienced by 42.9% of patients who
received IV morphine compared to none in the pare-
coxib group; no other side effects were noted. Only 1
patient in the morphine group required rescue medica-
tion compared to 5 patients (27.8%) in the parecoxib
group. All patients in the morphine group evaluated
morphine as an excellent or good drug whereas only 15
patients in the parecoxib group evaluated parecoxib as
an excellent or good drug (Table 1).
Discussion
In the practice of emergency and acute care medicine,
pain is the most frequent symptom in patients with a
wide variety of injuries and illness. Indeed, numerous
studies have proved the high prevalence of pain in the
ED, ranging from 70% to 80% [11,12]. Thus, evaluation
and management of acute pain is a fundamental element
in the ED and acute care medicine. Good pain manage-
ment is one of the major elements that correlate with
patients’ satisfaction in the ED [13].
Even though the management of pain in the ED has
improved with the usage of morphine as a gold standardTable 2 Comparison of mean NRS between patients











0 7.8 (1.3) 7.09, 8.41
5 5.7 (2.2) 4.77, 6.71
15 4.7 (2.3) 3.66, 5.64
30 3.9 (2.3) 2.93, 4.77
Morphine 0 7.1 (1.3) 6.38, 7.88 0.095
5 4.5 (1.7) 3.44, 5.65
15 3.1 (1.6) 1.94, 4.19
30 2.0 (1.4) 0.99, 3.09
*Repeated measure ANOVA.
Figure 1 Estimated mean of NRS between patients treated with IV parecoxib sodium or IV morphine based on time.
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have limited its usage in polytrauma patients especially
with concomitant head injury. It can cause nausea,
vomiting, sedation, respiratory depression, delirium, and
myoclonus [16]. The variability of prescribing opioid an-
algesics in painful conditions such as ankle fracture was
present among emergency physicians from the American
College of Emergency Physicians [17]. In fact, physicians’
preference toward non-steroidal anti-inflammatory drugs
can be seen in some of the EDs [18].
The emergence of IV parecoxib sodium as a first par-
enteral selective COX-2 inhibitor has provided an alter-
native for the analgesic of choice for pain management
especially in postoperative pain management. From ourTable 3 Comparison of mean reduction of NRS within patient
on time
Comparison Parecoxib sodium
Time (minutes) Mean (SD) 95% CI P
0–5 2.0 (1.3) 1.34, 2.66 <
0–15 3.1 (1.8) 2.24, 3.98 <
0–30 3.9 (1.8) 3.05, 4.84 <
5–15 1.1 (0.9) 0.66, 1.56 <
5–30 1.9 (1.2) 1.37, 2.52 <
15–30 0.8 (0.8) 0.44, 1.22 <study, there was a non-significant trend toward superior-
ity of IV morphine over IV parecoxib. The mean NRS at
30 minutes for the parecoxib group was 3.9 (SD ± 2.3)
whereas that for the morphine group was 2.4 (SD ± 1.4).
Even though there was no statistically significant differ-
ence between these two groups, patients who received
IV morphine were able to achieve better pain control
than those in the parecoxib group. All patients in the IV
morphine group evaluated it as an excellent or good
drug.
Both groups were also able to achieve significant pain
reduction based on time within their groups (Table 2).
Patients who received IV parecoxib showed a significant
reduction from 0 to 5, 15, and 30 minutes. Meanwhile,treated with IV parecoxib sodium or IV morphine based
Morphine
value Mean (SD) 95% CI P value
0.001 2.5 (1.5) 1.70, 3.44 <0.001
0.001 4.1 (1.3) 3.34, 4.80 <0.001
0.001 5.1 (1.3) 4.31, 5.84 <0.001
0.001 1.5 (1.2) 0.83, 2.17 <0.001
0.001 2.5 (1.6) 1.57, 3.43 <0.001
0.001 1.0 (1.3) 0.25, 1.75 0.013
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nificant reduction for most of the time, except between
15–30 minutes. This is understood as IV morphine was
able to reduce the magnitude of pain score faster than
parecoxib (Figure 1). It also showed better reduction of
NRS in the morphine group compared to the parecoxib
group within the study period, even though the graph
patterns were almost parallel. Figure 1 also shows that the
perceptible analgesic effect occurred as fast as 5 minutes
in the parecoxib group, which is comparable with a previ-
ous clinical study [2].
Based on the pain management research, both drugs
had achieved minimal clinically significant difference
(MCSD) of pain after treatment, even at 5 minutes after
drug administration. Bijur et al. concluded that MCSD
for NRS was 1.3 [19], whereas Kendrick and Strout
found the NRS difference was 1.39 ± 1.05 [20]. Even
though there was no statistically significant difference
between IV parecoxib and IV morphine, and both drugs
had achieved MCSD, one of the important factors to be
determined was the magnitude of treatment effect that
matters for patients in acute pain [21]. From Table 1 and
Figure 1, IV morphine has shown to have better magni-
tude of pain reduction between these two drugs. In fact,
there were 5 patients (27.8%) that required rescue medi-
cation in the parecoxib group.
However, almost 50% of patients who received IV
morphine developed side effects of dizziness, whereas
none in the parecoxib group did. This is comparable
with a previous study that found no association with
opioid related side-effects in the parecoxib group [3].
Nevertheless, one study noted that dizziness was the
most frequently reported treatment-related side effect in
comparing parecoxib and ketoprofen, with an incidence
for dizziness in parecoxib vs. ketoprofen of 2.9% and
0.6%, respectively [9]. A possible explanation for the lack
of side effects in the parecoxib group in this study is the
short observation period, which was 30 minutes.
The present study was limited by the small sample size
and it was likely underpowered to detect a significant dif-
ference. Furthermore, its observation period of 30 minutes
was probably too short to determine the efficacy and
side effects of parecoxib as its peak effect occurs
within 2 hours of IV administration.
Conclusions
IV parecoxib has potential as an analgesic alternative to
morphine in acute trauma pain in the ED. Looking at its
effectiveness and lack of opioid-related side-effects, the
usage of IV parecoxib sodium may be extended further
to a variety of cases in the ED. Its morphine-sparing
effects are also an advantage to minimize the dose of
morphine should the patient require opioids during the
continuation of care in the emergency setting.Abbreviations
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